Tevogen reports 60% rise in institutional stock ownership

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) reported institutional ownership of its common stock increased 60% as of March 31, 2025, compared to December 31, 2024, according to Form 13F filings with the Securities and Exchange Commission.

The Warren, New Jersey-based company said Vanguard and BlackRock led the growth, increasing their combined holdings by 151%. Among 51 institutional investment managers holding Tevogen stock as of March 31, 2025, 73% increased or maintained their positions.

The company noted only one current institutional holder also owned Tevogen stock during the same period in 2024, indicating an influx of new institutional investors.

"Increased institutional ownership is widely regarded as a sign of confidence in a company's fundamentals and long-term growth potential," said Tapan Shah, Tevogen's Head of Investor Relations.

Shah cited the company's AI advancements, including new patent activity and a collaboration with Microsoft and Databricks, along with plans to establish its own GMP cell manufacturing facility for developing targeted therapies for cancers and infectious diseases.

Tevogen said it will provide another institutional ownership update following the next SEC reporting period. The information was based on a company press release.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Third Coast Bancshares sells subsidiary assets to Gulf Coast for $27.5M
• Banzai prices $0.9M public offering at $2.75 per share